Mona Darwish, PhD

ENHANCE Trial: Adherence to Current Antipsychotic and Adjunctive Pimavanserin in Patients With Schizophrenia and Inadequate Response to Antipsychotic Treatment

Up to 70% of individuals with schizophrenia experience inadequate response to antipsychotic treatment potentially due to insufficient exposure due to nonadherence or to medication ineffec...

Brandon Abbs , PhD;

Mona Darwish , PhD;

Dragana Bugarski-Kirola , MD, MBA, MSc;

Yuan Liu , MSc;

Srdjan Stankovic , MD, MSPH;

10/27/2020

Stereotactic radiosurgery for palliative management of hepatocellular carcinoma associated with portal vein thrombosis

Background The life expectancy and treatment options for the patients with hepatocellular carcinoma HCC presented with portal vein thrombosis are frustrating. This study...

K. Abdelkarim ;

W. Hamed ;

M. ElGharib ;

G. Esmat ;

Mona Darwish , PhD;

M. Elebrashi ;

06/27/2022

Exposure-Response Modeling From the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder

Pimavanserin, a selective serotonin inverse agonist/antagonist at the 5-HT2A/C receptors, is being actively studied for multiple indications. The CLARITY clinical trial program is evaluat...

Srdjan Stankovic , MD, MSPH;

Julie Passarell , MA;

Becky Howell , MA, MBA;

Joel Owen , PhD;

Mona Darwish , PhD;

Bryan Dirks , MD, MSc, MBA;

10/27/2020